105 tracked 13F filers disclose a position in TECX as of the latest SEC 13F filings, a combined $414.7M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $87.1M | 2.8M | ▲+0.3% Added · +9K sh | Q1 2026 | |
| 2 | TCG Crossover Management, LLC | $37.2M | 1.2M | ▲New +1.2M sh | Q1 2026 | |
| 3 | Aberdeen Group plc | $35.3M | 1.1M | —Held | Q1 2026 | |
| 4 | BlackRock, Inc. | $26.6M | 860K | ▲+0.7% Added · +6K sh | Q1 2026 | |
| 5 | BRAIDWELL LP | $26.2M | 847K | ▼−8.7% Reduced · −80K sh | Q1 2026 | |
| 6 | First Light Asset Management, LLC | $20.0M | 648K | ▲New +648K sh | Q1 2026 | |
| 7 | BAKER BROS. ADVISORS LP | $18.8M | 608K | ▼−33% Reduced · −296K sh | Q1 2026 | |
| 8 | 5AM Venture Management, LLC | $18.8M | 607K | —Held | Q1 2026 | |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $14.6M | 474K | →First observed position No prior filed position | Q1 2026 | |
| 10 | Vestal Point Capital, LP | $10.1M | 328K | —Held | Q1 2026 | |
| 11 | KENNEDY CAPITAL MANAGEMENT LLC | $8.9M | 287K | ▲+37% Added · +77K sh | Q1 2026 | |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | $8.3M | 268K | ▲+1.8% Added · +5K sh | Q1 2026 | |
| 13 | MARSHALL WACE, LLP | $7.1M | 230K | ▲+643% Added · +199K sh | Q1 2026 | |
| 14 | ORBIMED ADVISORS LLC | $7.0M | 227K | ▼−61% Reduced · −348K sh | Q1 2026 | |
| 15 | STATE STREET CORP | $6.6M | 214K | ▲+2.1% Added · +4K sh | Q1 2026 | |
| 16 | Squarepoint Ops LLC | $5.1M | 164K | ▼−18% Reduced · −35K sh | Q1 2026 | |
| 17 | PRICE T ROWE ASSOCIATES INC /MD/ | $5.1M | 164K | ▲New +164K sh | Q1 2026 | |
| 18 | Ikarian Capital, LLC | $4.9M | 158K | ▲New +158K sh | Q1 2026 | |
| 19 | AMERIPRISE FINANCIAL INC | $4.4M | 143K | ▲New +143K sh | Q1 2026 | |
| 20 | Opaleye Management Inc. | $3.8M | 123K | ▼−43% Reduced · −92K sh | Q1 2026 | |
| 21 | Soleus Capital Management, L.P. | $3.8M | 122K | ▲New +122K sh | Q1 2026 | |
| 22 | D. E. Shaw & Co., Inc. | $3.6M | 116K | ▼−3.4% Reduced · −4K sh | Q1 2026 | |
| 23 | WELLS FARGO & COMPANY/MN | $3.5M | 113K | ▼−6.4% Reduced · −8K sh | Q1 2026 | |
| 24 | Woodline Partners LP | $3.1M | 100K | ▼−50% Reduced · −100K sh | Q1 2026 | |
| 25 | ExodusPoint Capital Management, LP | $2.6M | 84K | ▼−25% Reduced · −28K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 15 funds opened a new position in TECX and 12 added to an existing one, while 20 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| ELI LILLY & COLLY | 43 funds | $33.2B |
| BOSTON SCIENTIFIC CORPBSX | 42 funds | $5.9B |
| REVOLUTION MEDICINES INCRVMD | 42 funds | $2.3B |
| BRISTOL-MYERS SQUIBB COBMY | 41 funds | $6.1B |
| MERCK & CO. INC.MRK | 40 funds | $11.4B |
| INTUITIVE SURGICAL INCISRG | 39 funds | $12.2B |
| UNITEDHEALTH GROUP INCUNH | 39 funds | $11.9B |
| GILEAD SCIENCES INCGILD | 39 funds | $9.2B |
| THERMO FISHER SCIENTIFIC INCTMO | 39 funds | $7.2B |
| RHYTHM PHARMACEUTICALS INCRYTM | 39 funds | $1.1B |
| IONIS PHARMACEUTICALS INCIONS | 39 funds | $1.1B |
| DANAHER CORPDHR | 38 funds | $7.3B |
Ranked by how many of TECX's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | McNamara Peter | Chief Scientific Officer | Sell (S) | 172 | $6K |
| May 4, 2026 | Ruddy Marcella K. | Chief Medical Officer | Sell (S) | 1K | $32K |
| Apr 1, 2026 | Ruddy Marcella K. | Chief Medical Officer | Sell (S) | 1K | $31K |
| Mar 6, 2026 | McNamara Peter | Chief Scientific Officer | Sell (S) | 215 | $8K |
| Mar 6, 2026 | McNamara Peter | Chief Scientific Officer | Sell (S) | 6K | $181K |
| Mar 6, 2026 | Ruddy Marcella K. | Chief Medical Officer | Sell (S) | 10K | $300K |
| Mar 4, 2026 | McNamara Peter | Chief Scientific Officer | Sell (S) | 2K | $41K |
| Mar 3, 2026 | McNamara Peter | Chief Scientific Officer | Sell (S) | 2K | $36K |
| Feb 11, 2026 | REICIN ALISE | Chief Executive Officer, Director | Buy (P) | 3K | $53K |
| Feb 10, 2026 | Lochner Daniel | Chief Financial Officer | Buy (P) | 6K | $130K |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director, 10% Owner | Buy (P) | 54K | $876K |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director, 10% Owner | Buy (P) | 9K | $155K |
Connected entities for TECX
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/TECX/capital-change-brief"
Use Arkolith's capital_change_brief for TECX. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for TECX. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.